866-997-4948(US-Canada Toll Free)

Renal Cell Carcinoma - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 793 Pages

Renal Cell Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Renal Cell Carcinoma Pipeline Review, H2 2016, provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape.

Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule. Symptoms include hematuria, loin pain, abdominal mass, malaise, which is a general feeling of feeling unwell, weight loss and/or loss of appetite, anemia resulting from depression of erythropoietin and erythrocytosis. The predisposing factors are age and hereditary factors. The disease is controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Renal Cell Carcinoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Renal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 46, 42, 3, 34, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 4 molecules, respectively.Renal Cell Carcinoma.

Renal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Renal Cell Carcinoma Overview 8
Therapeutics Development 9
Renal Cell Carcinoma - Therapeutics under Development by Companies 11
Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 18
Renal Cell Carcinoma - Pipeline Products Glance 19
Renal Cell Carcinoma - Products under Development by Companies 23
Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34
Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35
Renal Cell Carcinoma - Therapeutics Assessment 130
Drug Profiles 162
Renal Cell Carcinoma - Dormant Projects 738
Renal Cell Carcinoma - Discontinued Products 753
Renal Cell Carcinoma - Product Development Milestones 757
Appendix 775

List of Tables
Number of Products under Development for Renal Cell Carcinoma, H2 2016 26
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2016 27
Number of Products under Development by Companies, H2 2016 28
Number of Products under Development by Companies, H2 2016 (Contd..1) 29
Number of Products under Development by Companies, H2 2016 (Contd..2) 30
Number of Products under Development by Companies, H2 2016 (Contd..3) 31
Number of Products under Development by Companies, H2 2016 (Contd..4) 32
Number of Products under Development by Companies, H2 2016 (Contd..5) 33
Number of Products under Development by Companies, H2 2016 (Contd..6) 34
Number of Products under Investigation by Universities/Institutes, H2 2016 35
Comparative Analysis by Late Stage Development, H2 2016 36
Comparative Analysis by Clinical Stage Development, H2 2016 37
Comparative Analysis by Early Stage Development, H2 2016 38
Comparative Analysis by Unknown Stage Development, H2 2016 39
Products under Development by Companies, H2 2016 40
Products under Development by Companies, H2 2016 (Contd..1) 41
Products under Development by Companies, H2 2016 (Contd..2) 42
Products under Development by Companies, H2 2016 (Contd..3) 43
Products under Development by Companies, H2 2016 (Contd..4) 44
Products under Development by Companies, H2 2016 (Contd..5) 45
Products under Development by Companies, H2 2016 (Contd..6) 46
Products under Development by Companies, H2 2016 (Contd..7) 47
Products under Development by Companies, H2 2016 (Contd..8) 48
Products under Development by Companies, H2 2016 (Contd..9) 49
Products under Development by Companies, H2 2016 (Contd..10) 50
Products under Investigation by Universities/Institutes, H2 2016 51
Renal Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016 52
Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016 53
Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 54
Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016 55
Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H2 2016 56
Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016 57
Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 58
Renal Cell Carcinoma - Pipeline by Apac Biotech Pvt Ltd, H2 2016 59
Renal Cell Carcinoma - Pipeline by arGEN-X BV, H2 2016 60
Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016 61
Renal Cell Carcinoma - Pipeline by ARMO Biosciences, Inc., H2 2016 62
Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 63
Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016 64
Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016 65
Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 66
Renal Cell Carcinoma - Pipeline by BIOCAD, H2 2016 67
Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016 68
Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016 69
Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 70
Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2016 71
Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 72
Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016 73
Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016 74
Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 75
Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 76
Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H2 2016 77
Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 78
Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016 79
Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016 80
Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 81
Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016 82
Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 83
Renal Cell Carcinoma - Pipeline by Five Prime Therapeutics Inc, H2 2016 84
Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016 85
Renal Cell Carcinoma - Pipeline by Genor BioPharma Co Ltd, H2 2016 86
Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016 87
Renal Cell Carcinoma - Pipeline by Hemispherx Biopharma, Inc., H2 2016 88
Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016 89
Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2016 90
Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2016 91
Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016 92
Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016 93
Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2016 94
Renal Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016 95
Renal Cell Carcinoma - Pipeline by Incuron, LLC, H2 2016 96
Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016 97
Renal Cell Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016 98
Renal Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016 99
Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H2 2016 100
Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 101
Renal Cell Carcinoma - Pipeline by KineMed, Inc., H2 2016 102
Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 103
Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H2 2016 104
Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016 105
Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016 106
Renal Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016 107
Renal Cell Carcinoma - Pipeline by Medivation, Inc., H2 2016 108
Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016 109
Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 110
Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 111
Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016 112
Renal Cell Carcinoma - Pipeline by Mologen AG, H2 2016 113
Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H2 2016 114
Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016 115
Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H2 2016 116
Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016 117
Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016 118
Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 119
Renal Cell Carcinoma - Pipeline by Omeros Corporation, H2 2016 120
Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016 121
Renal Cell Carcinoma - Pipeline by OncoMax, H2 2016 122
Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 123
Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016 124
Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016 125
Renal Cell Carcinoma - Pipeline by Pharmacyclics Inc, H2 2016 126
Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016 127
Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H2 2016 128
Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 129
Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016 130
Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016 131
Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016 132
Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics Inc, H2 2016 133
Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 134
Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 135
Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 136
Renal Cell Carcinoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 137
Renal Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 138
Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H2 2016 139
Renal Cell Carcinoma - Pipeline by Theravectys SA, H2 2016 140
Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016 141
Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 142
Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016 143
Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016 144
Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2016 145
Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H2 2016 146
Assessment by Monotherapy Products, H2 2016 147
Assessment by Combination Products, H2 2016 148
Number of Products by Stage and Target, H2 2016 150
Number of Products by Stage and Mechanism of Action, H2 2016 163
Number of Products by Stage and Route of Administration, H2 2016 176
Number of Products by Stage and Molecule Type, H2 2016 178
Renal Cell Carcinoma - Dormant Projects, H2 2016 754
Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016 755
Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016 756
Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016 757
Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016 758
Renal Cell Carcinoma - Dormant Projects (Contd..5), H2 2016 759
Renal Cell Carcinoma - Dormant Projects (Contd..6), H2 2016 760
Renal Cell Carcinoma - Dormant Projects (Contd..7), H2 2016 761
Renal Cell Carcinoma - Dormant Projects (Contd..8), H2 2016 762
Renal Cell Carcinoma - Dormant Projects (Contd..9), H2 2016 763
Renal Cell Carcinoma - Dormant Projects (Contd..10), H2 2016 764
Renal Cell Carcinoma - Dormant Projects (Contd..11), H2 2016 765
Renal Cell Carcinoma - Dormant Projects (Contd..12), H2 2016 766
Renal Cell Carcinoma - Dormant Projects (Contd..13), H2 2016 767
Renal Cell Carcinoma - Dormant Projects (Contd..14), H2 2016 768
Renal Cell Carcinoma - Discontinued Products, H2 2016 769
Renal Cell Carcinoma - Discontinued Products (Contd..1), H2 2016 770
Renal Cell Carcinoma - Discontinued Products (Contd..2), H2 2016 771
Renal Cell Carcinoma - Discontinued Products (Contd..3), H2 2016 772

List of Figures
Number of Products under Development for Renal Cell Carcinoma, H2 2016 26
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2016 27
Number of Products under Development by Companies, H2 2016 28
Number of Products under Investigation by Universities/Institutes, H2 2016 35
Comparative Analysis by Late Stage Development, H2 2016 36
Comparative Analysis by Clinical Stage Development, H2 2016 37
Comparative Analysis by Early Stage Products, H2 2016 38
Assessment by Monotherapy Products, H2 2016 147
Assessment by Combination Products, H2 2016 148
Number of Products by Top 10 Targets, H2 2016 149
Number of Products by Stage and Top 10 Targets, H2 2016 149
Number of Products by Top 10 Mechanism of Actions, H2 2016 162
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 162
Number of Products by Top 10 Routes of Administration, H2 2016 175
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 175
Number of Products by Top 10 Molecule Types, H2 2016 177
Number of Products by Stage and Top 10 Molecule Types, H2 2016 177

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *